- Home
- BARK vs IPHA Comparison
BARK vs IPHA Comparison
Compare BARK & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BARK
- IPHA
- Stock Information
- Founded
- BARK 2011
- IPHA 1999
- Country
- BARK United States
- IPHA France
- Employees
- BARK N/A
- IPHA N/A
- Industry
- BARK Department/Specialty Retail Stores
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- BARK Consumer Discretionary
- IPHA Health Care
- Exchange
- BARK Nasdaq
- IPHA Nasdaq
- Market Cap
- BARK 146.0M
- IPHA 160.1M
- IPO Year
- BARK N/A
- IPHA 2019
- Fundamental
- Price
- BARK $0.72
- IPHA $1.88
- Analyst Decision
- BARK Strong Buy
- IPHA Strong Buy
- Analyst Count
- BARK 3
- IPHA 3
- Target Price
- BARK $2.50
- IPHA $5.00
- AVG Volume (30 Days)
- BARK 1.2M
- IPHA 575.5K
- Earning Date
- BARK 11-10-2025
- IPHA 09-17-2025
- Dividend Yield
- BARK N/A
- IPHA N/A
- EPS Growth
- BARK N/A
- IPHA N/A
- EPS
- BARK N/A
- IPHA N/A
- Revenue
- BARK $451,690,000.00
- IPHA $14,839,695.00
- Revenue This Year
- BARK N/A
- IPHA $22.29
- Revenue Next Year
- BARK $6.25
- IPHA $43.84
- P/E Ratio
- BARK N/A
- IPHA N/A
- Revenue Growth
- BARK N/A
- IPHA N/A
- 52 Week Low
- BARK $0.66
- IPHA $1.41
- 52 Week High
- BARK $2.56
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- BARK 40.63
- IPHA 44.87
- Support Level
- BARK $0.66
- IPHA $1.73
- Resistance Level
- BARK $0.84
- IPHA $1.92
- Average True Range (ATR)
- BARK 0.05
- IPHA 0.13
- MACD
- BARK -0.01
- IPHA -0.01
- Stochastic Oscillator
- BARK 33.80
- IPHA 15.83
About BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.